Navigation Links
Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications
Date:3/12/2013

NEWTON, Mass., March 12, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, announced today that it has entered into an exclusive license agreement with the University of Bristol.  Under the terms of the agreement, the Company has acquired exclusive worldwide rights to use, for all skin applications, a novel method to manufacture a class of prostaglandins that reduces fat.  Additional terms were not disclosed. 

The revolutionary technology, which one expert has called "unbeatable in its conciseness and elegance", greatly simplifies synthesis of prostaglandins.  It is expected to improve manufacturing efficiency by 5-10 fold and substantially reduce manufacturing costs.  The technology, featured in the September 13th, 2012 issue of Nature magazine, was developed at the University of Bristol by Professor Varinder Aggarwal and colleagues.

"There is remarkable synergy between our research and Topokine's innovative products.  I look forward to helping advance Topokine's efforts by applying our synthesis technology," said Professor Aggarwal, a Fellow of the Royal Society who has joined Topokine's Advisory Board.

"Professor Aggarwal's group is at the cutting-edge of prostaglandin chemistry," said Murat Kalayoglu, MD, PhD, Topokine President & CEO.  "This exclusive license further enhances our IP position, and we are excited to collaborate with him and the University of Bristol."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat.  XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors.  XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

About the University of Bristol

The University of Bristol is consistently ranked among the leaders in UK higher education.  Research-intensive and with an international reputation for quality and innovation, the University has over 18,000 students from over 100 countries, together with more than 5,000 staff.  Places at Bristol are among the most highly sought after of all UK universities.  The University was founded in 1876 and was granted its Royal Charter in 1909.  It was the first university in England to admit women on the same basis as men.  It is located in the heart of the city from which it grew, but is now a significant player on the world stage as well as a major force in the economic, social and cultural life of Bristol and South West England.  Bristol is a member of the Worldwide Universities Network and of the Russell Group of leading research-intensive universities in the UK.

Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc., murat.kalayoglu@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
2. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
3. Shire Acquires Premacure AB
4. BD Acquires Cato Software Solutions
5. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
6. Dynamic Healthcare Services Acquires the operating assets of APO2, a Provider of Home Medical Equipment and Respiratory Therapy Products and Services in Hazleton, PA
7. PRA Acquires ClinStar
8. Endexx Acquires Medical Marijuana Management Technology
9. DSI Renal Acquires New Smyrna Beach Artificial Kidney Center
10. Henry Schein Acquires The Maddox Practice Group
11. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... JERUSALEM , April 28, 2016 ... ), a clinical-stage pharmaceutical company focused on the development of ... participate in the upcoming PIONEERS 2016 conference, presented by ... 5, 2016 in New York . ... overview at the conference. Presentation Details:   ...
(Date:4/27/2016)... April 27, 2016  Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended March ... of $0.24 increased 41.2%, and non-GAAP diluted EPS ... increased 5.8% on a reported basis, and 6.3% ... "We posted another good quarter, highlighted by 14.6% ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... Cosmetic Town, an online plastic surgery community, announces the relaunch ... recently revamped and upgraded to allow even more interaction between doctors and patients as ... According to the senior editor of Cosmetic Town, “We are excited that our ...
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now ... pots are frequently used by professional organic farmers and nurseries according to Sales Manager ... supply of fabric pots. Our goal is to offer wholesale level pricing and ultra-fast ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named Herr the ... of biomechatronics, technology that marries human physiology with electromechanics. He continues that work as ... the Founder of BionX , a leader in the field of prosthetic devices. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... of enterprise Data Center Infrastructure Management solutions, announces today the availability of ... enhancements in the area of capacity management and optimization, providing new analytical ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore solid evidence is ... true. But we toss the baby out with the bathwater when we ignore all ... identifying higher-quality studies and otherwise making better use of education policy research. , “When ...
Breaking Medicine News(10 mins):